driven jakafi
strength opex
adjust ep exclud non-cash one-tim item
headquart wilmington de biotechnolog compani develop drug treat cancer
autoimmun diseas lead drug jakafi approv rare blood cancer
octob report result revenu ep adjust higher
expect compani increas jakafi fy sale guidanc rang
jakafi sale compani anoth strong beat-and-rais quarter due jakafi strong sale
us yoy mainli driven volum volum yoy increas estim fy
jakafi sale close high end guidanc bottom line beat also benefit lower-than-
expect sg guidanc opex unchang estim fy expens
low end guidanc compani state jakafi launch acut graft-versus-host diseas gvhd
second line better initi anticip expect reflect jakafi sale
pipelin updat itacitinib initi phiii acut gvhd readout ye believ itacitinib
becom standard care estim peak sale pemigatinib track
approv new drug applic nda cholangiocarcinoma bile duct cancer file
data bladder cancer bigger indic expect late expect sale ramp
indic compani initi tumor agnost fgfr addit patient ww trial
topic jak vitiligo compani recent announc posit result phii even
better result demonstr long durat respons topic jakafi treatment vitiligo
patient updat result patient achiev improv facial vitiligo area
week compar week vitiligo affect million peopl us approv drug
diseas believ larg potenti market limit competit
share strong post due solid growth jakafi expect phiii updat itacitinib
gvhd ye catalyst share calcul pmv estim per share
margin safeti valuat support sum-of-the-part analysi key product peak sale
million except per share
exclud non-cash one-tim item
valuat sale multipl
billion
sale adjust clinic risk multipl adjust clinic risk
billion
million except per share
current market discount pmv
after-tax payment buy option convert holder privat market valu
jing research analyst prepar report herebi certifi view express report accur reflect analyst
person view subject compani secur research analyst receiv direct
indirect compens express specif recommend view report
public data april buy recommend
chang hold april buy januari
